While in vivo CAR-T therapies eliminate complex ex vivo manufacturing, they introduce a new critical variable: the patient's own immune system. The therapy's efficacy relies on modifying T-cells within the body, but each patient's immune status is different, especially after prior treatments. This makes optimizing and standardizing the dose a significant challenge compared to engineered cell therapies.

Unlike immunotherapy, where re-challenge after progression is dubious, there is an emerging clinical practice of re-challenging patients with the same antibody-drug conjugate (ADC), such as enfortumab vedotin (EV), after a treatment break forced by toxicity. Anecdotally, patients are showing great responses, highlighting a key area for prospective data generation.

Immunotherapy antibodies bind to immune cells for weeks or months, a pharmacodynamic (PD) effect far longer than their pharmacokinetic (PK) half-life. This long-lasting binding suggests that minor variations in infusion timing for subsequent doses are unlikely to impact overall outcomes, casting doubt on the study's core hypothesis.

The primary goal after managing immune checkpoint inhibitor (ICI)-induced ITP is resuming cancer therapy. Data shows most patients do not experience a relapse of ITP upon re-challenge with the ICI, allowing them to continue their effective cancer treatment.

In a data-free zone, a survey of 78 US oncologists revealed an emerging consensus to wait six months before re-challenging with EV-Pembro after prior immunotherapy. This demonstrates how clinical practice norms can form around arbitrary time points when definitive evidence on optimal treatment-free intervals is lacking.

Integrating next-gen SCLC treatments like T-cell engagers requires more than education; it demands a physical and operational overhaul. Community practices must build infrastructure for 24-hour observation and establish proactive partnerships with specialists like ophthalmologists to manage novel toxicities.

Despite its approval, the bispecific T-cell engager tarlatamab sees slower community adoption than prior SCLC drugs. The barrier is the logistical need for inpatient monitoring and specialized supportive care for potential cytokine release syndrome during the first two doses, a new challenge for community practices that suggests a university collaboration model.

The next major shift for CAR T-cell therapy is its integration into frontline treatment. Instead of being reserved for relapse, it's being tested as a consolidation therapy that could replace the standard two to three years of maintenance chemotherapy, dramatically shortening treatment duration.

The necessary delays for screening, eligibility, and logistical setup for clinical trials and novel agents like tarlatamab can take weeks. This makes them unsuitable for patients with rapid, aggressive disease progression, forcing clinicians to rely on older, faster-acting cytotoxic therapies instead.